Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Closed Good Friday 04-17 16:00:00 EDT

5.50

+0.18

+3.38%

盘后5.49

-0.01-0.18%

19:59 EDT

High5.54	Low5.24	Vol12.77M
Open5.32	D1 Closing5.32	Amplitude5.64%
Mkt Cap2.21B	Tradable Cap2.11B	Total Shares402.29M
T/O68.70M	T/O Rate3.33%	Tradable Shares382.98M
P/B2.14	ROE-61.89%	EPS-1.69
52wk High12.36	52wk Low3.79	P/E-3.25
Dividend0.00	Div.Yield0.00	ROA-28.48%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":5.5,"timestamp":1744920000000,"preClose":5.32,"halted":0,"volume":12766775,"hourTrading":{"tag":"盘后","latestPrice":5.49,"preClose":5.5,"latestTime":"19:59 EDT","volume":239168,"amount":1314623.1666,"timestamp":1744934387496},"delay":0,"floatShares":382978763,"shares":402287265,"eps":-1.690915,"marketStatus":"Closed Good Friday","change":0.18,"latestTime":"04-17 16:00:00 EDT","open":5.32,"high":5.535,"low":5.235,"amount":68701956.10176499,"amplitude":0.056391,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.690915,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":5.32,"preHourTrading":{"tag":"盘前","latestPrice":5.34,"preClose":5.32,"latestTime":"09:27 EDT","volume":127616,"amount":680736.9241599999,"timestamp":1744896476796},"postHourTrading":{"tag":"盘后","latestPrice":5.49,"preClose":5.5,"latestTime":"19:59 EDT","volume":239168,"amount":1314623.1666,"timestamp":1744934387496},"volumeRatio":0.3473709225069669,"impliedVol":1.1375,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/RXRX","defaultTab":"news","newsList":[{"id":"2528090520","title":"Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2528090520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528090520?lang=en_us&edition=full_marsco","pubTime":"2025-04-19 01:34","pubTimestamp":1744997654,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant advancements in its drug discovery initiatives and clinical studies, including dosing the first patient in a promising Phase 1 trial. Despite the broader market's flat performance over the past week, Recursion's stock price saw a 22% increase, suggesting that these developments reinforced investor confidence. The company's aim to accelerate drug discovery and clinical trials with enhanced data analytics may have added weight to this upward momentum.You should learn about the 4 possible red flags we've spotted with Recursion Pharmaceuticals .NasdaqGS:RXRX Earnings Per Share Growth as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-nasdaqgs-rxrx-taps-173414714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","RXRX","BK4611","BK4139","BK4539","BK4609"],"gpt_icon":1},{"id":"2527211273","title":"BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211273","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211273?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:42","pubTimestamp":1744807337,"startTime":"0","endTime":"0","summary":"BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World DataApril 16 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:HEALTHVERITY PARTNERS WITH RECURSION TO ENH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUAB5GPQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4539","BK4139","BK4548","BK4609","RXRX"],"gpt_icon":0},{"id":"2527241285","title":"HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241285","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241285?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:30","pubTimestamp":1744806600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data  technology and privacy-compliant data exchange, today announced that Recursion , a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4609","BK4539","BK4611","BK4548","RXRX","BK4139"],"gpt_icon":1},{"id":"2527943012","title":"Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527943012","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527943012?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 13:07","pubTimestamp":1744693671,"startTime":"0","endTime":"0","summary":"Wall Street’s main indices kicked off the trading week in the green territory, albeit with minimal gains, as investors stayed on the sidelines while continuing to digest President Donald Trump’s temporary tax reprieve on technology companies.The S&P 500 recorded the highest gain, up 0.79 percent, while the Dow Jones came second at 0.78 percent. The tech-heavy Nasdaq was also up by 0.64 percent.Meanwhile, 10 companies, predominantly in the technology sector, bucked a broader market optimism, booking modest declines during the session. In this article, let us explore Monday’s 10 worst performers and the reasons behind their gains.A pharmacist in a hospital pharmacy stands next to a row of various drug containers.According to the FDA, the initiative was designed to replace animal testing with “more effective human-relevant methods” in the development of monoclonal antibody therapies and other drugs.According to the FDA, it will begin to encourage the inclusion of New Approach Methodologie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-recursion-pharmaceuticals-inc-rxrx-050751253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","BK4609","BK4539","RXRX","BK4548","BK4139"],"gpt_icon":1},{"id":"2527117371","title":"Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527117371","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527117371?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 08:05","pubTimestamp":1744675508,"startTime":"0","endTime":"0","summary":"20:03 EDT Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-460k-shares-of-recursion-pharmaceuticals-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4585","BK4139","BK4609","BK4539","BK4544","BK4588","RXRX","BK4611","ARKK"],"gpt_icon":0},{"id":"2527140714","title":"Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527140714","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527140714?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 03:35","pubTimestamp":1744659310,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.  stands against other stocks that Jim Cramer discusses.In his latest appearance on CNBC’sSquawk on the Street, Jim Cramer suggested the recent tariffs might not simply be about economic leverage. He hinted at a deeper agenda within parts of the administration that goes beyond trade policy:. “There’s plenty of sense that something’s going to happen that’s going to take this away. In fact, just because of what we saw the other day with it going to 10 percent, I don’t see that at all. I think these are very different kinds of tariffs. I mean, this is a tariff where I think there’s some people with the administration who actually ultimately have a goal of regime change.“READ ALSO:Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key StocksandJim Cramer Questions Market Logic and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4609","BK4548","BK4611",".IXIC","USAW.SI","BK4539","PSQ","QID","TSYW.SI","NQmain","RXRX","TQQQ","QLD","BK4139","NVIW.SI","MNQmain","SQQQ"],"gpt_icon":1},{"id":"2527199861","title":"Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527199861","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527199861?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 21:09","pubTimestamp":1744636140,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  shares soared 27.7% in the last trading session to close at $5.76. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.1% loss over the past four weeks.Earlier this month, the company announced that it has dosed the first patient in its early-stage study of investigational candidate, REC-3565, for treating relapsed or refractory (R/R) B-cell lymphomas. REC-3565 is a selective MALT1 inhibitor developed using Recursion Pharmaceuticals’ proprietary AI-driven Recursion OS platform. The growing optimism related to this development might have driven the recent share price rally.For Recursion Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RXRX going forward to see if this recent jump can","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","BK4548","RXRX","AQST","BK4139","BK4007","BK4539","BK4609"],"gpt_icon":1},{"id":"2527995994","title":"Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527995994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527995994?lang=en_us&edition=full_marsco","pubTime":"2025-04-13 22:50","pubTimestamp":1744555838,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-bruker-brkr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RXRX","BK4548","BK4139","BK4611","BK4137","BK4121","BRKR","LU1815336091.USD","HCSG","LU0757428866.USD","BK4609","BK4539"],"gpt_icon":0},{"id":"2526902066","title":"Recursion Pharmaceuticals call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2526902066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526902066?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 00:05","pubTimestamp":1744387514,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 9,589 calls trading, 1.6x expected, and implied vol increasing over 27 points...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-22?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4609","BK4139","BK4539","RXRX","BK4548"],"gpt_icon":0},{"id":"2526698309","title":"Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698309?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERT","RXRX","BK4167","BK4539","BK4609","ABSI","BK4611","BK4121","BK4588","BK4585","BK4139","BK4548","SDGR"],"gpt_icon":0},{"id":"2526318698","title":"Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526318698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526318698?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 21:32","pubTimestamp":1744378357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4167","BK4539","BK4548","BK4611","RXRX","BK4121","CERT","BK4609","SDGR","BK4585","BK4588","ABSI"],"gpt_icon":0},{"id":"1146777405","title":"US FDA to Phase Out Animal Testing in Drug Development, Adopt AI Methods","url":"https://stock-news.laohu8.com/highlight/detail?id=1146777405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146777405?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 07:34","pubTimestamp":1744328047,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with \"human-relevant methods,\" including t","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","CRL","CERT","SDGR","RXRX"],"gpt_icon":1},{"id":"2526451593","title":"Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2526451593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526451593?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 00:23","pubTimestamp":1744302180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 12:23 ET (16:23 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9b4e43bbb37604adaeb10a55d437a8b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","BK4504","LU0158827781.USD","BK4539","BK4588","IE00BKVL7J92.USD","LU0225283273.USD","BK4534","LU1668664300.SGD","RXRX","LU0106831901.USD","LU2357305700.SGD","BK4139","LU1989772840.SGD","LU0314104364.USD","BK4548","LU1548497426.USD","BK4581","LU1363072403.SGD","LU2028103732.USD","LU0158827948.USD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU2347655156.SGD","BK4585","LU1720051017.SGD","LU2271345857.HKD","BK4127","BK4516","LU0795875086.SGD","LU0795875169.SGD","LU0098860793.USD","LU2023251221.USD","LU1162221912.USD","LU2133065610.SGD","LU1074936037.SGD","BK4611","BK4609","LU0320765646.SGD","LU2089283258.USD","LU0267386448.USD","LU2111349929.HKD","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","LU0912757837.SGD","LU0006306889.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2526569360","title":"Recursion Pharmaceuticals price target lowered to $8 from $10 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2526569360","media":"TIPRANKS","labels":["rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526569360?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:30","pubTimestamp":1744288212,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $8 from $10 and keeps an Equal Weight rating on the shares. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-8-from-10-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-8-from-10-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RXRX"],"gpt_icon":0},{"id":"2526559363","title":"Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559363","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559363?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:00","pubTimestamp":1744200000,"startTime":"0","endTime":"0","summary":"Kyiv, Ukraine and Salt Lake City, UT, April  09, 2025  (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058339/0/en/Recursion-and-Enamine-Release-New-AI-Enabled-Targeted-Compound-Libraries.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4548","RXRX","BK4539","BK4139","BK4611"],"gpt_icon":1},{"id":"2525922298","title":"Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2525922298","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525922298?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:59","pubTimestamp":1744117160,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas.The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK inhibitor, the company said.The two-part study will also evaluate REC-3565 as a monotherapy to identify a recommended dose for combination regimens, Recursion Pharmaceuticals added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","BK4609","BK4548","RXRX","BK4611"],"gpt_icon":1},{"id":"2525892567","title":"Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525892567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525892567?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:55","pubTimestamp":1744116900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:55 ET (12:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX"],"gpt_icon":0},{"id":"2525962738","title":"Recursion Announces First Patient Dosed in Phase 1 Clinical Study of Rec-3565, a Selective Malt1 Inhibitor for Relapsed or Refractory B-Cell Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2525962738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525962738?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:00","pubTimestamp":1744113604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nTUAB0P48Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","RXRX","BK4548","BK4139","BK4609","BK4539"],"gpt_icon":0},{"id":"2525899567","title":"Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899567","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899567?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake Ci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057532/0/en/Recursion-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-REC-3565-a-Selective-MALT1-Inhibitor-for-Relapsed-or-Refractory-B-cell-Lymphomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4609","BK4539","BK4611","REC","RXRX","BK4548"],"gpt_icon":1},{"id":"2525602988","title":"Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2525602988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525602988?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:51","pubTimestamp":1744109493,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-positioning-and-operational-resilience-justify-buy-rating-for-recursion-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-positioning-and-operational-resilience-justify-buy-rating-for-recursion-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":0.2195},{"period":"1month","weight":-0.1393},{"period":"3month","weight":-0.1577},{"period":"6month","weight":-0.2075},{"period":"1year","weight":-0.2637},{"period":"ytd","weight":-0.1864}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050758},{"month":2,"riseRate":0.5,"avgChangeRate":0.092727},{"month":3,"riseRate":0,"avgChangeRate":-0.270652},{"month":4,"riseRate":0.25,"avgChangeRate":-0.148721},{"month":5,"riseRate":0.5,"avgChangeRate":0.168429},{"month":6,"riseRate":0.5,"avgChangeRate":0.118076},{"month":7,"riseRate":0.75,"avgChangeRate":0.213595},{"month":8,"riseRate":0.25,"avgChangeRate":-0.10569},{"month":9,"riseRate":0.25,"avgChangeRate":-0.072683},{"month":10,"riseRate":0,"avgChangeRate":-0.131747},{"month":11,"riseRate":0.5,"avgChangeRate":0.076362},{"month":12,"riseRate":0.25,"avgChangeRate":0.027925}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction